Navigation Links
New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
Date:3/31/2009

t causes myocardial infarction and stroke. The study's authors further concluded that the ability to identify postmenopausal women with an increased risk of arterial thrombosis or clotting before even starting estrogen therapy is an important goal to help physicians determine which women may be at the least risk to benefit from estrogen therapy.

"The effect of estrogen therapy on cardiovascular risk remains a point of controversy; however, these data suggest that estrogen delivered transdermally may not increase the likelihood of clotting for women who are at borderline risk," said Dr. Nachtigall. "This study supports the emerging data suggesting that oral, not transdermal estrogen may increase the risk of venous thromboembolism in postmenopausal women."

Transdermal estrogen therapies available by prescription offer effective, low-dose estrogen for the treatment of moderate to severe hot flashes associated with menopause and are administered in the form of gels, sprays and patches. Some include: estradiol gel 0.1% available in three doses 0.25, 0.5, and 1.0 mg estradiol; estradiol patches available in .025mg, .0375mg, .05mg, .075mg; and .1mg a transdermal estradiol mist spray. For more information about menopause management visit: www.menopause.org.

About NYU Langone Medical Center

Located in the heart of New York City, NYU Langone Medical Center is a premier center for health care, biomedical research, and medical education. For over 167 years, NYU physicians and researchers have contributed to the practice and science of medicine. Today the Medical Center consists of NYU School of Medicine; Rusk Institute of Rehabilitation Medicine, the first and largest facility of its kind; NYU Hospital for Joint Diseases, a leader in musculoskeletal care; and such nationally recogn
'/>"/>

SOURCE NYU Langone Medical Center
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced the ... the compounding, packaging and distributing of its naltrexone tablets.  The ... United States . KRS Global is ... tablets in various strengths for individual patients in response to ...
(Date:1/23/2015)... GAINESVILLE, Fla. , Jan. 23, 2015  HyGreen, Inc., ... distribution agreement and partnership with RCA Medical, a subsidiary ... Africa . Each year, hundreds of ... health care-associated infections as organisms are transmitted from patient ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Addrenex Pharmaceuticals today expanded its pipeline of ... of an agreement to license a new drug ... debilitating sleep disorder, as well as other neurologic ... Addrenex the worldwide rights (excluding East Asia) to ...
... Circassia Ltd, a specialty,biopharmaceutical company focused on allergy, ... clinical development programme for its ragweed allergy,therapy. The ... based on Circassia,s ToleroMune(R) technology, which has previously,achieved ... allergies. Ragweed,is one of the leading causes of ...
Cached Medicine Technology:Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy 2Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy 3Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy 2
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... risk of unintentionally overdosing on over-the-counter (OTC) pain medication, ... Dr. Michael Wolf, from Northwestern University in Chicago, and ... potential misuse of pain medication containing the active ingredient ... online in the Journal of General Internal Medicine ...
... Patricia Dickson, M.D., principal investigator at The Los ... BioMed), is co-principal investigator of a project that was ... Institute for Regenerative Medicine (CIRM). The goal of ... therapy for the treatment of mucopolysaccharidosis I (MPS I), ...
... TUESDAY, May 29 (HealthDay News) -- If you want to ... say researchers who have found that centenarians are often extroverts ... The findings stem from the Longevity Genes Project, launched ... City. All the participants in the latest study were over ...
... of methotrexate (MTX) safety data found that injection ... superior to oral therapy in long-term treatment of ... in Arthritis Care & Research , a ... (ACR), suggest that with similar efficacy and tolerability ...
... A popular European fitness routine called Nordic walking improves the ... study. In Nordic walking, people walk with poles and ... skiing. This fast-growing form of exercise in Europe is safe ... quality of life and reduces their risk of hospitalization, but ...
... STANFORD, Calif. A specific antioxidant supplement may be ... to a pilot trial from the Stanford University School ... 31 children with the disorder. The antioxidant, called ... as well as reducing the children,s repetitive behaviors. The ...
Cached Medicine News:Health News:Misuse of over-the-counter pain medication is potential health threat 2Health News:LA BioMed's Dr. Patricia Dickson researching treatments for neurodegenerative disorders 2Health News:Optimism, Laughter May Bring Long Life 2Health News:Optimism, Laughter May Bring Long Life 3Health News:Injection of methotrexate not superior to oral therapy in juvenile arthritis treatment 2Health News:'Nordic Walking' a Winner for Heart Failure Patients, Study Says 2Health News:Antioxidant shows promise as treatment for certain features of autism, Stanford study finds 2Health News:Antioxidant shows promise as treatment for certain features of autism, Stanford study finds 3
Used for arthroscopic or open shoulder surgery. Powered positioning of back section inclines from 0 degrees to 90 degrees. Removable shoulder panels provide an eight-inch (203-mm) access area behind ...
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
... an important part in our daily lives. ... changes can cause severe handicaps. A decisive ... prostheses was to produce a reconstructed joint ... as nearly possible.,The cementless RM Finger System ...
... the use of sand bags under the drape during ... shaped for optimal foot contact and positioning the leg ... be used under the drape by attaching it to ... for use on top of the drape. It can ...
Medicine Products: